RecruitingNot ApplicableNCT05828823

Incremental Hemodialysis: The TwoPlus Trial

Comparative Effectiveness of an Individualized Model of Hemodialysis Versus Conventional Hemodialysis


Sponsor

Wake Forest University Health Sciences

Enrollment

350 participants

Start Date

Feb 26, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function. The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patient eligibility Criteria:
  • Age ≥ 18 years
  • Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 12 weeks
  • Has received ≤36 sessions of intermittent HD (i.e., on HD for ≤12 weeks) at the time patient is approached for potential study participation
  • Kidney urea clearance \<2.0 mL/min
  • Urine volume# of ≥500 mL/24 h

Exclusion Criteria13

  • Pre-HD serum K ≥5.8 mEq/L, Na ≤125 mEq/L, or bicarbonate level ≤17 mEq/L
  • Requirement or anticipated requirement of high-volume ultrafiltration
  • Unable or unwilling to follow the study protocol for any reason
  • Known pregnancy or planning to attempt to become pregnant or lactating women
  • Estimated survival or dialysis modality change or center transfer \<6 months
  • Caregiver Eligibility Criteria:
  • be at least 18 years old
  • be the main caregiver (at patient's choice)
  • be a close relative of the patient (spouse, child, sibling, parent, grandchild)
  • have no known psychiatric and neurologic disorders (through direct inquiry from the person)
  • not be a member of the medical or healthcare team
  • not be the caregiver for another patient with chronic illness
  • not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)

Interventions

DEVICEHemodialysis twice weekly

Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)

OTHERHemodialysis thrice weekly

Conventional hemodialysis regimen


Locations(10)

University of Florida

Jacksonville, Florida, United States

Emory University

Atlanta, Georgia, United States

Johns Hopkins University School of Medicine (JHUSM)

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Renal Research Institute (RRI)

New York, New York, United States

Northwell Health

Queens, New York, United States

University of North Carolina Chapel Hill

Chapel Hill, North Carolina, United States

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, United States

University of Virginia (UVA)

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05828823


Related Trials